Updated:
Sight Sciences
Paul Badawi and David Badawi founded Sight Sciences in 2011, headquartered in Menlo Park, California.
Sight Sciences
Paul Badawi and David Badawi founded Sight Sciences in 2011, headquartered in Menlo Park, California. The company developed a two-product platform targeting the interventional ophthalmology market — a departure from traditional pharmaceutical-first approaches to glaucoma and dry eye. Sight Sciences raised private capital from investors including D1 Capital Partners and KKR before listing on Nasdaq under the ticker SGHT in July 2021. The firm's commercial portfolio consists of the OMNI Surgical System, a handheld device for canaloplasty and trabeculotomy procedures that reduce intraocular pressure in glaucoma patients, and the TearCare System, a wearable eyelid-warming device for meibomian gland dysfunction, the leading cause of dry eye disease. Both products carry FDA 510(k) clearance. Sight Sciences generates revenue by selling capital equipment and single-use procedural kits to ophthalmologists and optometrists across the United States — its primary market — with early-stage distribution in select European countries. The OMNI device holds a dedicated Category I CPT code for canaloplasty, and TearCare received a unique Healthcare Common Procedure Coding System (HCPCS) code in 2023, which the company states simplifies physician reimbursement. Sight Sciences reported 226 full-time employees as of its 2023 annual filing. The firm operates a single facility in Menlo Park. In February 2024, the company announced a strategic reorganization that included a workforce reduction of approximately 15% to align operating expenses with revised revenue guidance (per the firm's SEC filing, February 2024). The firm does not disclose a charitable foundation or adjacent investment vehicles. The structural distinction of Sight Sciences lies in its pairing of a surgical-interventional device model with aggressive pursuit of dedicated procedural reimbursement codes — a path more common among medical-device incumbents than venture-backed startups. That reimbursement architecture, not just the device IP, functions as the economic moat, because it transforms physician adoption from a cash-pay proposition into an insured, repeatable procedure business.
General information
Firm type
Unclassified
Year founded
2011
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Menlo Park
Corporate office
Menlo Park, CA, United States
Principals
Paul Badawi
Co-Founder and CEO
David Badawi
Co-Founder and Chief Technology Officer
Sector focus
Frequently asked questions
What is the core clinical problem Sight Sciences is solving?
Sight Sciences targets glaucoma and dry eye disease, two of the most prevalent ophthalmic conditions. Glaucoma affects over 3 million Americans and is traditionally managed with daily eye drops that suffer from poor patient adherence — OMNI provides a one-time surgical alternative that reduces reliance on medication. Dry eye disease affects roughly 16 million diagnosed Americans, and TearCare addresses the root meibomian gland problem rather than masking symptoms with artificial tears.
How does Sight Sciences generate revenue?
Sight Sciences sells the OMNI Surgical System and TearCare System as capital equipment to ophthalmology and optometry practices, then derives recurring revenue from single-use disposable procedural kits. OMNI procedures are reimbursed under a dedicated Category I CPT code (66174 for canaloplasty), and in 2023 TearCare received its own HCPCS Level II code (E0650), which the company expects to broaden payer coverage and physician adoption.
Is Sight Sciences profitable?
As of its most recent public filings, Sight Sciences has not reported GAAP profitability. The company has funded operations through private venture capital, its 2021 IPO, and product revenue. The February 2024 workforce reduction was specifically aimed at reducing operating expenses to accelerate the timeline to cash-flow breakeven, as stated in the company's SEC filing.
What is Sight Sciences' competitive position relative to larger ophthalmology device companies?
Sight Sciences competes against large-cap medical-device firms including Alcon, Johnson & Johnson Vision, and Glaukos. Its differentiation lies in its dual-product focus on interventional glaucoma and dry eye, with reimbursement codes specific to its OMNI and TearCare procedures. The company's market-share growth depends on expanding utilization among existing accounts and converting physicians who currently manage glaucoma primarily with pharmaceuticals.
What regulatory clearances does Sight Sciences hold?
Both OMNI and TearCare hold FDA 510(k) clearance for their respective indications in the United States. OMNI is cleared for canaloplasty and trabeculotomy procedures. The company also holds CE Mark certification for distribution in select European markets, though the United States remains the dominant revenue geography.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: